Literature DB >> 19797073

Long-term immunity to lethal acute or chronic type II Toxoplasma gondii infection is effectively induced in genetically susceptible C57BL/6 mice by immunization with an attenuated type I vaccine strain.

Jason P Gigley1, Barbara A Fox, David J Bzik.   

Abstract

C57BL/6 (B6) mice are genetically highly susceptible to chronic type II Toxoplasma gondii infections that invariably cause lethal toxoplasmic encephalitis. We examined the ability of an attenuated type I vaccine strain to elicit long-term immunity to lethal acute or chronic type II infections in susceptible B6 mice. Mice immunized with the type I cps1-1 vaccine strain were not susceptible to a lethal (100-cyst) challenge with the type II strain ME49. Immunized mice challenged with 10 ME49 cysts exhibited significant reductions in brain cyst and parasite burdens compared to naive mice, regardless of the route of challenge infection. Remarkably, cps1-1 strain-immunized B6 mice chronically infected with ME49 survived for at least 12 months without succumbing to the chronic infection. Potent immunity to type II challenge infections persisted for at least 10 months after vaccination. While the cps1-1 strain-elicited immunity did not prevent the establishment of a chronic infection or clear established brain cysts, cps1-1 strain-elicited CD8(+) immune T cells significantly inhibited recrudescence of brain cysts during chronic ME49 infection. In addition, we show that uracil starvation of the cps1-1 strain induces early markers of bradyzoite differentiation. Collectively, these results suggest that more effective immune control of chronic type II infection in the genetically susceptible B6 background is established by vaccination with the nonreplicating type I uracil auxotroph cps1-1 strain.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19797073      PMCID: PMC2786442          DOI: 10.1128/IAI.00649-09

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  57 in total

1.  IL-15 prolongs the duration of CD8+ T cell-mediated immunity in mice infected with a vaccine strain of Toxoplasma gondii.

Authors:  I A Khan; L Casciotti
Journal:  J Immunol       Date:  1999-10-15       Impact factor: 5.422

2.  Recent expansion of Toxoplasma through enhanced oral transmission.

Authors:  C Su; D Evans; R H Cole; J C Kissinger; J W Ajioka; L D Sibley
Journal:  Science       Date:  2003-01-17       Impact factor: 47.728

3.  Synergistic role of CD4+ and CD8+ T lymphocytes in IFN-gamma production and protective immunity induced by an attenuated Toxoplasma gondii vaccine.

Authors:  R T Gazzinelli; F T Hakim; S Hieny; G M Shearer; A Sher
Journal:  J Immunol       Date:  1991-01-01       Impact factor: 5.422

4.  Protective effects of immunization with a recombinant cyst antigen in mouse models of infection with Toxoplasma gondii tissue cysts.

Authors:  Stephen Parmley; Teri Slifer; Fausto Araujo
Journal:  J Infect Dis       Date:  2002-02-15       Impact factor: 5.226

5.  MHC class I gene(s) in the D/L region but not the TNF-alpha gene determines development of toxoplasmic encephalitis in mice.

Authors:  Y Suzuki; K Joh; O C Kwon; Q Yang; F K Conley; J S Remington
Journal:  J Immunol       Date:  1994-11-15       Impact factor: 5.422

Review 6.  Toxoplasmic encephalitis in AIDS.

Authors:  B J Luft; J S Remington
Journal:  Clin Infect Dis       Date:  1992-08       Impact factor: 9.079

7.  Live and killed vaccines against toxoplasmosis in mice.

Authors:  H Waldeland; J K Frenkel
Journal:  J Parasitol       Date:  1983-02       Impact factor: 1.276

8.  Acute cerebral toxoplasmosis is induced by in vivo neutralization of TNF-alpha and correlates with the down-regulated expression of inducible nitric oxide synthase and other markers of macrophage activation.

Authors:  R T Gazzinelli; I Eltoum; T A Wynn; A Sher
Journal:  J Immunol       Date:  1993-10-01       Impact factor: 5.422

9.  The use of irradiated vaccine in immunization against experimental murine toxoplasmosis.

Authors:  S K Seah; G Hucal
Journal:  Can J Microbiol       Date:  1975-09       Impact factor: 2.419

10.  Toxoplasma encephalitis in congenic B10 and BALB mice: impact of genetic factors on the immune response.

Authors:  M Deckert-Schlüter; D Schlüter; D Schmidt; G Schwendemann; O D Wiestler; H Hof
Journal:  Infect Immun       Date:  1994-01       Impact factor: 3.441

View more
  20 in total

Review 1.  The CD8 T-cell road to immunotherapy of toxoplasmosis.

Authors:  Rajarshi Bhadra; Jason P Gigley; Imtiaz A Khan
Journal:  Immunotherapy       Date:  2011-06       Impact factor: 4.196

2.  The IL-12- and IL-23-Dependent NK Cell Response Is Essential for Protective Immunity against Secondary Toxoplasma gondii Infection.

Authors:  Daria L Ivanova; Tiffany M Mundhenke; Jason P Gigley
Journal:  J Immunol       Date:  2019-10-11       Impact factor: 5.422

Review 3.  CD8+ T cell immunity in an encephalitis model of Toxoplasma gondii infection.

Authors:  SuJin Hwang; Imtiaz A Khan
Journal:  Semin Immunopathol       Date:  2015-05-06       Impact factor: 9.623

4.  Role of CD4+ Foxp3+ Regulatory T Cells in Protection Induced by a Live Attenuated, Replicating Type I Vaccine Strain of Toxoplasma gondii.

Authors:  Haroon Akbar; Isabelle Dimier-Poisson; Nathalie Moiré
Journal:  Infect Immun       Date:  2015-06-29       Impact factor: 3.441

5.  Type II Toxoplasma gondii KU80 knockout strains enable functional analysis of genes required for cyst development and latent infection.

Authors:  Barbara A Fox; Alejandra Falla; Leah M Rommereim; Tadakimi Tomita; Jason P Gigley; Corinne Mercier; Marie-France Cesbron-Delauw; Louis M Weiss; David J Bzik
Journal:  Eukaryot Cell       Date:  2011-04-29

6.  Avirulent uracil auxotrophs based on disruption of orotidine-5'-monophosphate decarboxylase elicit protective immunity to Toxoplasma gondii.

Authors:  Barbara A Fox; David J Bzik
Journal:  Infect Immun       Date:  2010-07-06       Impact factor: 3.441

7.  Mast cell activator compound 48/40 is not an effective adjuvant for UV-attenuated Toxoplasma gondii vaccine.

Authors:  Xi Li; Shengjie Chen; Shiguang Huang; Fangli Lu
Journal:  Parasitol Res       Date:  2017-06-01       Impact factor: 2.289

8.  Immunity in the spleen and blood of mice immunized with irradiated Toxoplasma gondii tachyzoites.

Authors:  Nahiara Esteves Zorgi; Andrés Jimenez Galisteo; Maria Notomi Sato; Nanci do Nascimento; Heitor Franco de Andrade
Journal:  Med Microbiol Immunol       Date:  2016-01-05       Impact factor: 3.402

9.  Upregulated expression of Tim-3 involved in the process of toxoplasmic encephalitis in mouse model.

Authors:  Bin Wu; Bo Huang; Ying Chen; Shaoyuan Li; Junping Yan; Huanqin Zheng; Shiguang Huang; Jilong Shen; Zhao-Rong Lun; Yong Wang; Lloyd H Kasper; Fangli Lu
Journal:  Parasitol Res       Date:  2013-04-18       Impact factor: 2.289

Review 10.  Targeting tumors with nonreplicating Toxoplasma gondii uracil auxotroph vaccines.

Authors:  Barbara A Fox; Kiah L Sanders; Shan Chen; David J Bzik
Journal:  Trends Parasitol       Date:  2013-08-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.